eduKateSG · Why Science?
Run one protocol across regions while planning population diversity, care differences, enrolment, consistency, statistical power and operational quality so global evidence remains interpretable
Read FDA’s final July 2018 ICH E17 guidance through early regulatory dialogue, intrinsic and extrinsic factors, regional allocation, sample size, randomisation, pooled analysis, treatment-effect consistency, regional estimates, trial operations and global submission.
A medicine may be developed for patients across many countries, yet disease, genetics, diet, care, diagnosis and treatment practice can vary by region. A multi-regional trial must learn one global answer without erasing meaningful differences.
FDA lists ICH E17, General Principles for Planning and Design of Multi-Regional Clinical Trials, as final guidance dated July 2018. FDA says the aim is to increase the acceptability of MRCT data in global regulatory submissions.
Did you know? E17 defines an MRCT as a trial conducted in more than one region under a single protocol. One protocol improves coordination, but regional enrolment and operational consistency still need deliberate design.
For students, an MRCT is a worldwide team experiment: every site follows one scientific plan while the analysis asks whether geography changes who participated, how treatment worked or how evidence should be interpreted.
Chapter index
Chapters 1–9: FDA final July 2018 ICH E17 guidance
- 1. E17 supports globally interpretable evidence under one protocol
- 2. FDA lists E17 as final guidance from July 2018
- 3. Early regulatory dialogue aligns the global development strategy
- 4. A region is defined for the scientific question
- 5. Intrinsic factors describe participant characteristics
- 6. Extrinsic factors describe environment and medical practice
- 7. The target population supports both global and regional questions
- 8. Regional sample allocation is planned rather than accidental
- 9. Randomisation and stratification protect treatment comparison
Chapters 10–17: multi-regional clinical trials, global development, regional allocation, consistency, pooled analysis and operational quality
- 10. A common endpoint needs common meaning
- 11. Pooled analysis answers the primary global question
- 12. Consistency assessment explores regional treatment effects
- 13. Regional estimates carry uncertainty
- 14. Pharmacokinetics can explain some regional differences
- 15. Operational consistency protects against false geography
- 16. Missing data and intercurrent events may vary by region
- 17. A complete E17 receipt reconstructs the global trial logic
CHAPTER 1 OF 17 · Plan one global question
1. E17 supports globally interpretable evidence under one protocol
The guidance focuses on MRCTs intended for submissions to multiple authorities. It addresses planning, design and analysis so pooled results and regional relevance can be assessed together.
The scientific value of e17 supports globally interpretable evidence under one protocol appears when the clinical question, ethical duty and evidence decision remain connected. The guidance focuses on MRCTs intended for submissions to multiple authorities. It addresses planning, design and analysis so pooled results and regional relevance can be assessed together. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
Try this
Build an evidence receipt for e17 supports globally interpretable evidence under one protocol. Trace e17 supports globally interpretable evidence under one protocol from global question through regional allocation, pooled model and interpretation. Add the source version, population, comparison and decision rule. Keep this limit: Regional estimates are often imprecise and should not be read as separate small trials.
A strong science note separates observation from interpretation. Trace e17 supports globally interpretable evidence under one protocol from global question through regional allocation, pooled model and interpretation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace e17 supports globally interpretable evidence under one protocol from global question through regional allocation, pooled model and interpretation. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
CHAPTER 2 OF 17 · Plan one global question
2. FDA lists E17 as final guidance from July 2018
The official page explains that global development increasingly relies on MRCTs and identifies acceptability across regions as the purpose. A current receipt records the July 2018 final guidance and regional implementation requirements.
For fda lists e17 as final guidance from july 2018, a reliable conclusion depends on both participant experience and the controlled study system. The official page explains that global development increasingly relies on MRCTs and identifies acceptability across regions as the purpose. A current receipt records the July 2018 final guidance and regional implementation requirements. Preserve this guardrail: Regions must be prespecified for scientific and regulatory reasons.
Try this
Challenge the assumptions behind fda lists e17 as final guidance from july 2018. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind fda lists e17 as final guidance from july 2018. Test one realistic source of bias or uncertainty and record what changes. Respect this boundary: Regions must be prespecified for scientific and regulatory reasons.
A strong science note separates observation from interpretation. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind fda lists e17 as final guidance from july 2018. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind fda lists e17 as final guidance from july 2018. Keep this boundary visible: Regions must be prespecified for scientific and regulatory reasons.
CHAPTER 3 OF 17 · Plan one global question
3. Early regulatory dialogue aligns the global development strategy
Authorities may differ in medical practice, unmet need and evidentiary expectations. Discussion before protocol finalisation can address target regions, population, endpoints, allocation, analysis and potential regional concerns.
A trustworthy account of early regulatory dialogue aligns the global development strategy keeps design, conduct, analysis and interpretation in one traceable route. Authorities may differ in medical practice, unmet need and evidentiary expectations. Discussion before protocol finalisation can address target regions, population, endpoints, allocation, analysis and potential regional concerns. Remember: Operational inconsistency can mimic biological heterogeneity.
Try this
Audit the study route for early regulatory dialogue aligns the global development strategy. Reconstruct early regulatory dialogue aligns the global development strategy from enrolment, deviations, regional estimates and uncertainty. Mark every handoff where consent, identity, time, geography, bias or units could be lost. Preserve this caution: Operational inconsistency can mimic biological heterogeneity.
A strong science note separates observation from interpretation. Reconstruct early regulatory dialogue aligns the global development strategy from enrolment, deviations, regional estimates and uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reconstruct early regulatory dialogue aligns the global development strategy from enrolment, deviations, regional estimates and uncertainty. Keep this boundary visible: Operational inconsistency can mimic biological heterogeneity.
CHAPTER 4 OF 17 · Plan one global question
4. A region is defined for the scientific question
A geographical country, area or grouping may be appropriate depending on population, care and regulatory purpose. Regions are prespecified rather than redrawn after results to produce a preferred pattern.
The scientific value of a region is defined for the scientific question appears when the clinical question, ethical duty and evidence decision remain connected. A geographical country, area or grouping may be appropriate depending on population, care and regulatory purpose. Regions are prespecified rather than redrawn after results to produce a preferred pattern. Keep this boundary visible: A pooled effect does not erase clinically important regional differences.
Try this
Build an evidence receipt for a region is defined for the scientific question. Reassess a region is defined for the scientific question after new exposure, care-pattern, population or implementation evidence appears. Add the source version, population, comparison and decision rule. Keep this limit: A pooled effect does not erase clinically important regional differences.
A strong science note separates observation from interpretation. Reassess a region is defined for the scientific question after new exposure, care-pattern, population or implementation evidence appears. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess a region is defined for the scientific question after new exposure, care-pattern, population or implementation evidence appears. Keep this boundary visible: A pooled effect does not erase clinically important regional differences.
CHAPTER 5 OF 17 · Represent regional diversity
5. Intrinsic factors describe participant characteristics
Genetics, age, sex, body size, organ function and disease biology can influence exposure or response. Development data identify which factors deserve representation, stratification, adjustment or subgroup assessment.
For intrinsic factors describe participant characteristics, a reliable conclusion depends on both participant experience and the controlled study system. Genetics, age, sex, body size, organ function and disease biology can influence exposure or response. Development data identify which factors deserve representation, stratification, adjustment or subgroup assessment. Preserve this guardrail: Regional estimates are often imprecise and should not be read as separate small trials.
Try this
Challenge the assumptions behind intrinsic factors describe participant characteristics. Trace intrinsic factors describe participant characteristics from global question through regional allocation, pooled model and interpretation. Test one realistic source of bias or uncertainty and record what changes. Respect this boundary: Regional estimates are often imprecise and should not be read as separate small trials.
A strong science note separates observation from interpretation. Trace intrinsic factors describe participant characteristics from global question through regional allocation, pooled model and interpretation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace intrinsic factors describe participant characteristics from global question through regional allocation, pooled model and interpretation. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
CHAPTER 6 OF 17 · Represent regional diversity
6. Extrinsic factors describe environment and medical practice
Diet, culture, adherence, healthcare access, diagnosis, standard treatment and concomitant medicines can vary. Site training alone cannot remove every genuine regional difference.
A trustworthy account of extrinsic factors describe environment and medical practice keeps design, conduct, analysis and interpretation in one traceable route. Diet, culture, adherence, healthcare access, diagnosis, standard treatment and concomitant medicines can vary. Site training alone cannot remove every genuine regional difference. Remember: Regions must be prespecified for scientific and regulatory reasons.
Try this
Audit the study route for extrinsic factors describe environment and medical practice. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind extrinsic factors describe environment and medical practice. Mark every handoff where consent, identity, time, geography, bias or units could be lost. Preserve this caution: Regions must be prespecified for scientific and regulatory reasons.
A strong science note separates observation from interpretation. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind extrinsic factors describe environment and medical practice. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind extrinsic factors describe environment and medical practice. Keep this boundary visible: Regions must be prespecified for scientific and regulatory reasons.
CHAPTER 7 OF 17 · Represent regional diversity
7. The target population supports both global and regional questions
Eligibility criteria create a population relevant to intended use while avoiding unnecessary restrictions. Recruitment plans check whether important age, disease and treatment subgroups will actually enrol.
The scientific value of the target population supports both global and regional questions appears when the clinical question, ethical duty and evidence decision remain connected. Eligibility criteria create a population relevant to intended use while avoiding unnecessary restrictions. Recruitment plans check whether important age, disease and treatment subgroups will actually enrol. Keep this boundary visible: Operational inconsistency can mimic biological heterogeneity.
Try this
Build an evidence receipt for the target population supports both global and regional questions. Reconstruct the target population supports both global and regional questions from enrolment, deviations, regional estimates and uncertainty. Add the source version, population, comparison and decision rule. Keep this limit: Operational inconsistency can mimic biological heterogeneity.
A strong science note separates observation from interpretation. Reconstruct the target population supports both global and regional questions from enrolment, deviations, regional estimates and uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reconstruct the target population supports both global and regional questions from enrolment, deviations, regional estimates and uncertainty. Keep this boundary visible: Operational inconsistency can mimic biological heterogeneity.
CHAPTER 8 OF 17 · Represent regional diversity
8. Regional sample allocation is planned rather than accidental
Allocation considers disease prevalence, recruitment feasibility, intrinsic and extrinsic factors, statistical precision and regional regulatory needs. A region with too few participants may yield an unstable local estimate.
For regional sample allocation is planned rather than accidental, a reliable conclusion depends on both participant experience and the controlled study system. Allocation considers disease prevalence, recruitment feasibility, intrinsic and extrinsic factors, statistical precision and regional regulatory needs. A region with too few participants may yield an unstable local estimate. Preserve this guardrail: A pooled effect does not erase clinically important regional differences.
Try this
Challenge the assumptions behind regional sample allocation is planned rather than accidental. Reassess regional sample allocation is planned rather than accidental after new exposure, care-pattern, population or implementation evidence appears. Test one realistic source of bias or uncertainty and record what changes. Respect this boundary: A pooled effect does not erase clinically important regional differences.
A strong science note separates observation from interpretation. Reassess regional sample allocation is planned rather than accidental after new exposure, care-pattern, population or implementation evidence appears. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess regional sample allocation is planned rather than accidental after new exposure, care-pattern, population or implementation evidence appears. Keep this boundary visible: A pooled effect does not erase clinically important regional differences.
CHAPTER 9 OF 17 · Analyse pooled and regional evidence
9. Randomisation and stratification protect treatment comparison
Central randomisation, regional or other prespecified stratification and balanced enrolment can prevent chance or operational imbalances. Too many strata can create complexity and sparse cells, so choices remain purposeful.
A trustworthy account of randomisation and stratification protect treatment comparison keeps design, conduct, analysis and interpretation in one traceable route. Central randomisation, regional or other prespecified stratification and balanced enrolment can prevent chance or operational imbalances. Too many strata can create complexity and sparse cells, so choices remain purposeful. Remember: Regional estimates are often imprecise and should not be read as separate small trials.
Try this
Audit the study route for randomisation and stratification protect treatment comparison. Trace randomisation and stratification protect treatment comparison from global question through regional allocation, pooled model and interpretation. Mark every handoff where consent, identity, time, geography, bias or units could be lost. Preserve this caution: Regional estimates are often imprecise and should not be read as separate small trials.
A strong science note separates observation from interpretation. Trace randomisation and stratification protect treatment comparison from global question through regional allocation, pooled model and interpretation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace randomisation and stratification protect treatment comparison from global question through regional allocation, pooled model and interpretation. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
CHAPTER 10 OF 17 · Analyse pooled and regional evidence
10. A common endpoint needs common meaning
Definitions, assessment schedules, language versions, instruments, adjudication and clinical practice are harmonised. Measurement invariance and cultural interpretation matter when patient-reported outcomes cross languages.
The scientific value of a common endpoint needs common meaning appears when the clinical question, ethical duty and evidence decision remain connected. Definitions, assessment schedules, language versions, instruments, adjudication and clinical practice are harmonised. Measurement invariance and cultural interpretation matter when patient-reported outcomes cross languages. Keep this boundary visible: Regions must be prespecified for scientific and regulatory reasons.
Try this
Build an evidence receipt for a common endpoint needs common meaning. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind a common endpoint needs common meaning. Add the source version, population, comparison and decision rule. Keep this limit: Regions must be prespecified for scientific and regulatory reasons.
A strong science note separates observation from interpretation. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind a common endpoint needs common meaning. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind a common endpoint needs common meaning. Keep this boundary visible: Regions must be prespecified for scientific and regulatory reasons.
CHAPTER 11 OF 17 · Analyse pooled and regional evidence
11. Pooled analysis answers the primary global question
The prespecified model estimates the overall treatment effect across enrolled regions. Covariates, stratification factors and multiplicity are handled according to the protocol and statistical plan.
For pooled analysis answers the primary global question, a reliable conclusion depends on both participant experience and the controlled study system. The prespecified model estimates the overall treatment effect across enrolled regions. Covariates, stratification factors and multiplicity are handled according to the protocol and statistical plan. Preserve this guardrail: Operational inconsistency can mimic biological heterogeneity.
Try this
Challenge the assumptions behind pooled analysis answers the primary global question. Reconstruct pooled analysis answers the primary global question from enrolment, deviations, regional estimates and uncertainty. Test one realistic source of bias or uncertainty and record what changes. Respect this boundary: Operational inconsistency can mimic biological heterogeneity.
A strong science note separates observation from interpretation. Reconstruct pooled analysis answers the primary global question from enrolment, deviations, regional estimates and uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reconstruct pooled analysis answers the primary global question from enrolment, deviations, regional estimates and uncertainty. Keep this boundary visible: Operational inconsistency can mimic biological heterogeneity.
CHAPTER 12 OF 17 · Analyse pooled and regional evidence
12. Consistency assessment explores regional treatment effects
Regional estimates, interactions, graphical displays and contextual factors help identify important heterogeneity. Lack of significance in a small region is not automatically evidence of no effect.
A trustworthy account of consistency assessment explores regional treatment effects keeps design, conduct, analysis and interpretation in one traceable route. Regional estimates, interactions, graphical displays and contextual factors help identify important heterogeneity. Lack of significance in a small region is not automatically evidence of no effect. Remember: A pooled effect does not erase clinically important regional differences.
Try this
Audit the study route for consistency assessment explores regional treatment effects. Reassess consistency assessment explores regional treatment effects after new exposure, care-pattern, population or implementation evidence appears. Mark every handoff where consent, identity, time, geography, bias or units could be lost. Preserve this caution: A pooled effect does not erase clinically important regional differences.
A strong science note separates observation from interpretation. Reassess consistency assessment explores regional treatment effects after new exposure, care-pattern, population or implementation evidence appears. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess consistency assessment explores regional treatment effects after new exposure, care-pattern, population or implementation evidence appears. Keep this boundary visible: A pooled effect does not erase clinically important regional differences.
CHAPTER 13 OF 17 · Operate one protocol consistently
13. Regional estimates carry uncertainty
Confidence intervals can be wide when enrolment is limited. Interpretation considers effect direction, magnitude, precision, baseline risk, exposure and operations rather than demanding identical numerical results everywhere.
The scientific value of regional estimates carry uncertainty appears when the clinical question, ethical duty and evidence decision remain connected. Confidence intervals can be wide when enrolment is limited. Interpretation considers effect direction, magnitude, precision, baseline risk, exposure and operations rather than demanding identical numerical results everywhere. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
Try this
Build an evidence receipt for regional estimates carry uncertainty. Trace regional estimates carry uncertainty from global question through regional allocation, pooled model and interpretation. Add the source version, population, comparison and decision rule. Keep this limit: Regional estimates are often imprecise and should not be read as separate small trials.
A strong science note separates observation from interpretation. Trace regional estimates carry uncertainty from global question through regional allocation, pooled model and interpretation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace regional estimates carry uncertainty from global question through regional allocation, pooled model and interpretation. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
CHAPTER 14 OF 17 · Operate one protocol consistently
14. Pharmacokinetics can explain some regional differences
Exposure data and population analyses can connect dose, intrinsic factors and response across regions. A dosing approach may need adjustment where clinically relevant exposure differences are supported.
For pharmacokinetics can explain some regional differences, a reliable conclusion depends on both participant experience and the controlled study system. Exposure data and population analyses can connect dose, intrinsic factors and response across regions. A dosing approach may need adjustment where clinically relevant exposure differences are supported. Preserve this guardrail: Regions must be prespecified for scientific and regulatory reasons.
Try this
Challenge the assumptions behind pharmacokinetics can explain some regional differences. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind pharmacokinetics can explain some regional differences. Test one realistic source of bias or uncertainty and record what changes. Respect this boundary: Regions must be prespecified for scientific and regulatory reasons.
A strong science note separates observation from interpretation. Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind pharmacokinetics can explain some regional differences. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Challenge intrinsic factors, extrinsic factors, measurement and operational consistency behind pharmacokinetics can explain some regional differences. Keep this boundary visible: Regions must be prespecified for scientific and regulatory reasons.
CHAPTER 15 OF 17 · Operate one protocol consistently
15. Operational consistency protects against false geography
Site selection, training, supply, monitoring, laboratory methods, endpoint assessment and data systems follow common standards. Regional patterns caused by protocol deviations or measurement drift are investigated.
A trustworthy account of operational consistency protects against false geography keeps design, conduct, analysis and interpretation in one traceable route. Site selection, training, supply, monitoring, laboratory methods, endpoint assessment and data systems follow common standards. Regional patterns caused by protocol deviations or measurement drift are investigated. Remember: Operational inconsistency can mimic biological heterogeneity.
Try this
Audit the study route for operational consistency protects against false geography. Reconstruct operational consistency protects against false geography from enrolment, deviations, regional estimates and uncertainty. Mark every handoff where consent, identity, time, geography, bias or units could be lost. Preserve this caution: Operational inconsistency can mimic biological heterogeneity.
A strong science note separates observation from interpretation. Reconstruct operational consistency protects against false geography from enrolment, deviations, regional estimates and uncertainty. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reconstruct operational consistency protects against false geography from enrolment, deviations, regional estimates and uncertainty. Keep this boundary visible: Operational inconsistency can mimic biological heterogeneity.
CHAPTER 16 OF 17 · Operate one protocol consistently
16. Missing data and intercurrent events may vary by region
Withdrawal, rescue treatment, access to background therapy and follow-up can differ. Estimands, data collection and sensitivity analyses address these patterns without treating all missingness as equivalent.
The scientific value of missing data and intercurrent events may vary by region appears when the clinical question, ethical duty and evidence decision remain connected. Withdrawal, rescue treatment, access to background therapy and follow-up can differ. Estimands, data collection and sensitivity analyses address these patterns without treating all missingness as equivalent. Keep this boundary visible: A pooled effect does not erase clinically important regional differences.
Try this
Build an evidence receipt for missing data and intercurrent events may vary by region. Reassess missing data and intercurrent events may vary by region after new exposure, care-pattern, population or implementation evidence appears. Add the source version, population, comparison and decision rule. Keep this limit: A pooled effect does not erase clinically important regional differences.
A strong science note separates observation from interpretation. Reassess missing data and intercurrent events may vary by region after new exposure, care-pattern, population or implementation evidence appears. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Reassess missing data and intercurrent events may vary by region after new exposure, care-pattern, population or implementation evidence appears. Keep this boundary visible: A pooled effect does not erase clinically important regional differences.
CHAPTER 17 OF 17 · Operate one protocol consistently
17. A complete E17 receipt reconstructs the global trial logic
The record includes guidance version, regions and rationale, intrinsic and extrinsic factors, regulatory dialogue, population, regional allocation, randomisation and stratification, endpoint harmonisation, pooled model, consistency methods, exposure analysis, operations, deviations, missingness, regional estimates, uncertainty and conclusions.
For a complete e17 receipt reconstructs the global trial logic, a reliable conclusion depends on both participant experience and the controlled study system. The record includes guidance version, regions and rationale, intrinsic and extrinsic factors, regulatory dialogue, population, regional allocation, randomisation and stratification, endpoint harmonisation, pooled model, consistency methods, exposure analysis, operations, deviations, missingness, regional estimates, uncertainty and conclusions. Preserve this guardrail: Regional estimates are often imprecise and should not be read as separate small trials.
Try this
Challenge the assumptions behind a complete e17 receipt reconstructs the global trial logic. Trace a complete e17 receipt reconstructs the global trial logic from global question through regional allocation, pooled model and interpretation. Test one realistic source of bias or uncertainty and record what changes. Respect this boundary: Regional estimates are often imprecise and should not be read as separate small trials.
A strong science note separates observation from interpretation. Trace a complete e17 receipt reconstructs the global trial logic from global question through regional allocation, pooled model and interpretation. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.
Evidence checkpoint
Trace a complete e17 receipt reconstructs the global trial logic from global question through regional allocation, pooled model and interpretation. Keep this boundary visible: Regional estimates are often imprecise and should not be read as separate small trials.
Multi-regional trial map
| Question | Evidence to capture | Boundary to retain |
|---|---|---|
| What is shared? | One protocol and primary global question | Harmonise conduct |
| What may differ? | Intrinsic and extrinsic regional factors | Plan representation |
| What is estimated? | Pooled effect plus regional context | Prespecify analysis |
| What protects interpretation? | Allocation, measurement and operational consistency | Investigate heterogeneity |
Science learning becomes useful when a student can show where a claim came from, why it applies and where it stops. Continue with the eduKate Science Learning Hub, compare choices in the Education Hub, and connect these habits to career pathways built from subject capabilities.
E17 turns global research into one coordinated scientific conversation. The aim is not to make every region look identical; it is to understand diversity well enough that one trial can speak clearly to patients and regulators around the world.
Primary sources and verification date
Source status checked 26 October 2026. FDA guidance describes the agency’s current thinking and does not replace applicable statutes, regulations or product-specific communication with FDA.
- FDA: E17 Multi-Regional Clinical Trials — Final guidance, July 2018; checked 26 October 2026.
- ICH: Efficacy Guidelines — Official E17 guideline index and harmonisation context.
- FDA: ICH Guidance Documents — Current FDA index of implemented ICH clinical guidelines; checked 26 October 2026.
